Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Immulgnite Inc. operates a patent portfolio within the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action in the portfolio. This action is being handled by 1 distinct examiner within 1 distinct art unit. DUNN, LINDSAY MICHELLE is the busiest examiner for the portfolio, currently managing 1 busiest examiner pending action.
With only 1 pending office action, the prosecution workload is highly concentrated. Practitioners should tailor their approach to the specific tendencies of DUNN, LINDSAY MICHELLE, as this examiner oversees the entire pending pipeline. The focus within 1 distinct art unit suggests that the subject matter is specialized within the Biotechnology & Pharmaceuticals field. Resolving the 1 busiest examiner pending action will require a clear understanding of the examiner's previous actions and the technical standards of the assigned art unit. The alignment of the 1 pending office action with a single examiner in the Biotechnology & Pharmaceuticals sector indicates a streamlined path for this specific application.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUNN, LINDSAY MICHELLE | 1 | 80.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18460246 | TREATMENT OF HERPES SIMPLEX VIRUS INFECTION | DUNN, LINDSAY MICHELLE | 30d overdue |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18460246 | TREATMENT OF HERPES SIMPLEX VIRUS INFECTION | DUNN, LINDSAY MICHELLE | 1644 | §103§112 | Non-Final OA | 30d overdue | Pending | Sep 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImmulgnite Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Lindsay Michelle Dunn has the most, with 1 of Immulgnite Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
